Taiji Group morphine hydrochloride sustained release tablets applied for clinical trials accepted
-
Last Update: 2020-01-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On January 3, 2020, Taiji Group announced that southwest pharmaceutical, the holding subsidiary of the company, had received the acceptance notice of morphine hydrochloride sustained release tablets (24 osmotic pump type) clinical trial approved and issued by the State Food and drug administration Morphine hydrochloride sustained-release tablet (24h osmotic pump type) is a new sustained-release preparation developed by Southwest Pharmaceutical industry The drug is mainly applicable to the pain that other analgesic drugs are ineffective and need daily, continuous and long-term opioid analgesic treatment According to the World Health Organization
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.